接受辅助曲妥珠单抗治疗的乳腺癌患者左心房重构的心血管磁共振成像评估
这项前瞻性两中心纵向研究纳入41例HER2阳性乳腺癌女性,在曲妥珠单抗治疗前及治疗6、12、18个月行心脏MRI,发现左心房射血分数在6个月和12个月显著下降、左心房最小容积指数在12个月显著增加,18个月时均恢复至基线水平。
要点
- 曲妥珠单抗治疗期间左心房射血分数下降、左心房最小容积指数增加,停药6个月后恢复至基线。
- 治疗前6个月左心房射血分数变化与左心室射血分数变化相关(Spearman r=0.41,p=0.014)。
- 蒽环类药物使用与时间对左心房参数无显著交互作用(所有p>0.10)。
核心结论
- 在曲妥珠单抗治疗且心脏毒性发生率低的患者中,观察到左心房射血分数小幅但显著下降、左心房最小容积指数增加,持续整个治疗期并于停药6个月后恢复;提示曲妥珠单抗对心房和心室重构均有不良影响。
研究设计与样本
- 前瞻性两中心纵向研究,纳入41例接受12个月辅助曲妥珠单抗联合标准化疗的HER2阳性乳腺癌女性,在基线及开始曲妥珠单抗后6、12、18个月行系列心脏MRI,由盲法阅片者测量左心房容积,采用线性混合模型评估纵向变化。
关键影像表现/征象
- 与基线相比,左心房射血分数在6个月(62.7±5.7%,p=0.027)和12个月(62.2±6.1%,p=0.003)显著下降。
- 与基线相比,左心房最小容积指数在12个月显著增加(11.6±4.9 ml/m2 vs 13.8±4.5 ml/m2,p=0.002)。
- 18个月时所有指标较基线的变化均不再显著。
- 基线至6个月左心房射血分数变化与左心室射血分数变化相关(Spearman r=0.41,p=0.014)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: We evaluated left atrial (LA) remodeling using cardiac MRI (CMR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer during and after trastuzumab therapy.
METHODS: In this prospective 2-center longitudinal study, 41 women with HER2-positive breast cancer received adjuvant trastuzumab for 12 months, in addition to standard chemotherapy. Serial CMRs were performed at baseline, 6, 12, and 18 months after initiation of trastuzumab. LA volumes were measured by a blinded reader. Linear mixed model was used to evaluate longitudinal changes.
RESULTS: Of 41 women (mean age 52 ± 11 [SD] years; 56% received anthracycline), one patient experienced trastuzumab-induced cardiotoxicity (TIC) for which trastuzumab was interrupted for one cycle. Mean baseline left ventricular ejection fraction (LVEF) was 68.0 ± 5.9% and LA ejection fraction (LAEF) was 66.0 ± 6.6%. Compared to baseline, LAEF decreased significantly at 6 months (62.7 ± 5.7%, p = 0.027) and 12 months (62.2 ± 6.1%, p = 0.003), while indexed LA minimum volume (LAmin) significantly increased at 12 months (11.6 ± 4.9 ml/m2 vs 13.8 ± 4.5 ml/m2, p = 0.002). At 18 months, all changes from baseline were no longer significant. From baseline to 6 months, change in LAEF correlated with change in LVEF (Spearman's r = 0.41, p = 0.014). No significant interactions (all p > 0.10) were detected between time and anthracycline use for LA parameters.
CONCLUSIONS: Among trastuzumab-treated patients with low incidence of TIC, we observed a small but significant decline in LAEF and increase in LAmin that persisted for the duration of therapy and recovered 6 months after therapy cessation. These findings suggest that trastuzumab has concurrent detrimental effects on atrial and ventricular remodeling.
KEY POINTS: • In trastuzumab-treated breast cancer patients evaluated by cardiac MRI, left atrial ejection fraction declined and minimum volume increased during treatment and recovered to baseline after trastuzumab cessation. • Changes in left atrial ejection fraction correlated with changes in left ventricular ejection fraction in the first 6 months of trastuzumab treatment. • Trastuzumab therapy is associated with concurrent detrimental effects on left atrial and ventricular remodeling.
引用
- Huang, Brezden-Masley, Chan, et al. Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab. Eur Radiol. 2022. PMID: 34993574. doi:10.1007/s00330-021-08466-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。